Huynh of RBC Capital agreed, citing a survey by his firm of about 200 patients, payers, and prescribers: Our recent survey indicated that Foundayo would be a preferred oral option amongst patients since it has no dosing restrictions. Not so, Novo Nordisk CEO Maziar (Mike) Doustdar told CNBC last month: People are really interested because its the most efficacious pill right now in the market. Novo Nordisk cites efficacy Novo Nordisk sought to reinforce that message via an announcement trumpeting that its 25 mg dose of oral Wegovy showed significantly greater mean weight loss than the 36 mg dose of Foundayo, according to a population-adjusted indirect treatment comparison using data from two clinical trials: OASIS 4 (NCT05564117), a 307-patient randomized study which evaluated once-daily oral Wegovy 25 mg in overweight or obese adults with at least one self-reported unsuccessful dietary effort to lose body weight, to measure their percentage change in body weight and whether it was 5% at the end of treatment at week 64

P =0.0009) and fewer hospitalizations (2.3% vs 3.7%
Uremic toxins exert unique and detrimental effects on various biological processes, including the balance of pro-oxidative and anti-oxidative factors, mitochondrial function, inflammation, and ultimately lead to cellular senescence
2018 USRDS Annual Data Report: Epidemiology of kidney disease in the United States
What is a KLOW dosage chart
Davis said the supply chain for medications has also become more complicated